Brukinsa: Uses, Dosage, Side Effects, Warnings - Drugs.com https://www.drugs.com/brukinsa.

html

Brukinsa
Pronunciation: brew-KIN-za
Generic name: zanubrutinib
Dosage form: oral capsule
Drug class: BTK inhibitors

Medically reviewed by Carmen Pope, BPharm. Last updated on Mar 12, 2024.

What is Brukinsa?
Brukinsa (zanubrutinib) is a targeted treatment that is FDA-approved to treat adults with chronic
lymphocytic leukemia, small lymphocytic lymphoma (CLL/SLL), or Waldenström's macroglobulinemia
(WM).

It may also be given to treat adults with the following conditions under the accelerated approval
scheme; continued approval may be contingent upon clinical trial results:

• Mantle cell lymphoma (MCL) in those who have received at least one prior treatment

• Marginal zone lymphoma (MZL) that has returned or did not respond to treatment in those who
have received at least one anti-CD20-based regimen

• Relapsed or refractory follicular lymphoma (FL), in combination with obinutuzumab, after two or
more lines of systemic therapy.

Brukinsa directly inhibits an enzyme, called Bruton’s tyrosine kinase (BTK), by forming a covalent
bond with a cysteine residue on the enzyme, preventing its activity. BTK works as a signaling
molecule for the B-cell antigen receptor (BCR) and cytokine receptor pathways. Activation of these
pathways causes the proliferation of B cells and other interactions, and inhibition has been shown to
reduce the growth and spread of malignant B cells.

The ALPINE trial -- the first head-to-head phase 3 comparison trial of Brukinsa versus Imbruvica to be
conducted -- reported Brukinsa was more effective than Imbruvica for progression-free survival in
previously treated patients with relapsed or refractory CLL. Brukinsa also demonstrated a favorable
cardiac safety profile with significantly lower rates of atrial fibrillation/flutter (5.2% vs. 13.3%) and no
deaths due to cardiac disorders (vs 1.9% deaths with Imbruvica).

1 of 6 3/18/24, 17:25
Brukinsa: Uses, Dosage, Side Effects, Warnings - Drugs.com https://www.drugs.com/brukinsa.html

Brukinsa was first approved in 2019 for MCL, and subsequent approvals for other indications
followed.

Warnings
Serious hemorrhage, including intracranial or gastrointestinal hemorrhage, hematuria, and
hemothorax has occurred in people receiving Brukinsa, 0.3% have been fatal. 30% of people reported
bleeding of any grade, excluding purpura and petechiae. Coadministration with antiplatelet or
anticoagulants may increase the risk. Your doctor will monitor for signs and symptoms of bleeding and
discontinue if intracranial hemorrhage occurs. They may consider withholding Brukinsa for 3 to 7 days
pre and post surgery depending on the risk of bleeding. Report any signs of excessive bleeding to
your doctor.

Brukinsa affects your immune system. Serious bacterial, viral, or fungal infections have been reported
with Brukinsa; 2.9% were fatal and 24% were Grade 3 or higher. Reactivation of hepatitis B has also
occurred. Consider prophylaxis for herpes simplex virus, pneumocystis jirovecii pneumonia, and other
infections in patients who are at increased risk for infections. Monitor yourself for fever or other signs
and symptoms of infection and report them to your doctor.

Blood count abnormalities, including neutropenia, thrombocytopenia, and anemia, have occurred in
people receiving Brukinsa. Your doctor will perform regular blood counts and interrupt treatment,
reduce the dose, or discontinue treatment as warranted.

Serious cardiac arrhythmias, including Atrial fibrillation and atrial flutter, have been reported in patients
treated with Brukinsa. The risk is more likely in those with cardiac risk factors, high blood pressure,
and acute infections. Monitor yourself for signs and symptoms of cardiac arrhythmias (such as
palpitations, dizziness, dizziness when standing, and shortness of breath) and report these to your
doctor immediately.

Using Brukinsa may increase your risk of developing other cancers, such as non-melanoma skin
cancer. Ask your doctor about this risk and what skin symptoms to watch for. Wear protective clothing
and use sunscreen (SPF 30 or higher) when you are outdoors.

Brukinsa can cause fetal harm when administered to a pregnant woman, including malformations.
Women should use effective contraception and avoid becoming pregnant while taking Brukinsa and
for 1 week after the last dose. Men should avoid fathering a child during treatment and for 1 week
after the last dose.

It is not known if Brukinsa is safe and effective in children.

2 of 6 3/18/24, 17:25
Brukinsa: Uses, Dosage, Side Effects, Warnings - Drugs.com https://www.drugs.com/brukinsa.html

Before taking this medicine

Before you start treatment with Brukinsa, tell your healthcare provider about all of your medical
conditions, including if you:

• have bleeding problems

• have had recent surgery or plan to have surgery. Your healthcare provider may stop Brukinsa for
any planned medical, surgical, or dental procedure

• have an infection

• have or had heart rhythm problems

• have high blood pressure

• have liver problems, including a history of hepatitis B virus (HBV) infection

• take any other medicines, including prescription and over-the-counter medicines, vitamins, and
herbal supplements

• are pregnant or plan to become pregnant. Zanubrutinib can harm your unborn baby. If you can
become pregnant, your healthcare provider may do a pregnancy test before starting treatment
with this medicine.

You may need to have a negative pregnancy test before you start using Brukinsa. Females should not
become pregnant during treatment and for at least 1 week after the last dose. You should use
effective birth control (contraception) during treatment and for at least 1 week after the last dose.

Males should avoid getting female partners pregnant during treatment and for at least 1 week after
the last dose of Brukinsa. You should use effective birth control (contraception) during treatment and
for at least 1 week after the last dose.

Tell your doctor if you are breastfeeding or plan to breastfeed. It is not known if Brukinsa passes into
your breast milk. Do not breastfeed during treatment and for at least 2 weeks after your last dose.

Brukinsa pregnancy and breastfeeding warnings (more detail)

How should I take Brukinsa?

Take Brukinsa exactly as prescribed by your doctor. Follow all directions on your prescription label and
read all medication guides or instruction sheets. Use the medicine exactly as directed.

The recommended dosage is 160 mg orally twice daily or 320 mg once daily until disease progression

3 of 6 3/18/24, 17:25
Brukinsa: Uses, Dosage, Side Effects, Warnings - Drugs.com https://www.drugs.com/brukinsa.html

or unacceptable toxicity occurs.

• Capsules should be swallowed whole with a full glass of water.

• May be taken with or without food. Do not open, break, or chew the capsules.

• The dosage may need to be reduced in those with severe hepatic impairment.

Detailed Brukinsa dosage information

What happens if I miss a dose?

Take the missed dose on the same day you remember it. Take your next dose at the regular time and
stay on your once-daily schedule. Do not use 2 doses in one day.

What happens if I overdose?

Seek emergency medical attention or call the Poison Help line at 1-800-222-1222.

What are the side effects of Brukinsa?

Get emergency medical help if you have signs of an allergic reaction to Brukinsa: hives; difficulty
breathing; swelling of your face, lips, tongue, or throat.

Brukinsa can cause serious or life-threatening side effects. Call your doctor at once if you have:

• pounding heartbeats or fluttering in your chest

• chest discomfort

• a light-headed feeling, like you might pass out

• liver problems - right-sided upper stomach pain, vomiting, loss of appetite, yellowing of your skin
or eyes, and not feeling well

• low platelets in your blood - easy bruising, unusual bleeding, purple or red spots under your skin

• low red blood cells - pale skin, weakness, unusual tiredness, feeling light-headed or short of
breath, cold hands and feet, fast or irregular heartbeat

• low white blood cell counts - fever, mouth sores, skin sores, sore throat, cough, trouble breathing

• signs of bleeding inside your body - red or pink urine, bloody or tarry stools, coughing up blood or
vomit that looks like coffee grounds, severe headache, vision problems, numbness or weakness
on one side, trouble speaking or understanding what is said to you or

4 of 6 3/18/24, 17:25
Brukinsa: Uses, Dosage, Side Effects, Warnings - Drugs.com https://www.drugs.com/brukinsa.html

• signs of infection - fever, chills, redness or swelling, cough with mucus, feeling short of breath.

Your cancer treatments may be delayed or permanently discontinued if you have certain side effects.

Common Brukinsa side effects affecting more than 10% of people may include:

• diarrhea or constipation

• low platelet or other blood cell counts

• easy bruising or bleeding

• musculoskeletal pain

• high blood pressure

• rash or

• cold or flu symptoms such as stuffy nose, sneezing, sore throat, or cough.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice
about side effects. You may report side effects to the FDA at 1-800-FDA-1088.

Brukinsa side effects (more detail)

What other drugs will affect Brukinsa?

Sometimes it is not safe to use certain medications at the same time. Some drugs can affect your
blood levels of other drugs you take, which may increase side effects or make the medications less
effective. Common medications that may interact with Brukinsa include:

• Moderate to strong CYP3A Inhibitors, such as clarithromycin, nefazodone, itraconazole,

ketoconazole, atazanavir, ritonavir, grapefruit juice, erythromycin, or verapamil

• Moderate to strong CYP3A inducers, such as glucocorticoids, rifampin, carbamazepine,

phenobarbital, and phenytoin. Avoid coadministration.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-
counter medicines, vitamins, and herbal supplements. Taking Brukinsa with certain other medications
may affect how zanubrutinib works and can cause side effects.

Brukinsa drug interactions (more detail)

Storage

5 of 6 3/18/24, 17:25
Brukinsa: Uses, Dosage, Side Effects, Warnings - Drugs.com https://www.drugs.com/brukinsa.html

Store at room temperature 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C to 30°C
(59°F to 86°F).

Ingredients
Active: zanubrutinib 80mg

Inactive: Silicon dioxide, croscarmellose sodium, magnesium stearate, microcrystalline cellulose,

sodium lauryl sulfate, gelatine (unspecified), titanium dioxide, and ferrosoferric oxide.

Manufacturer
BeiGene, Ltd.

Frequently asked questions

• What are the names of the BTK inhibitors?

References

1. Product Label

Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to
your personal circumstances.

6 of 6 3/18/24, 17:25